United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to app… Read more
United Pharm - Asset Resilience Ratio
United Pharm (033270) has an Asset Resilience Ratio of 21.48% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how United Pharm's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down United Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩104.36 Billion | 21.48% |
| Total Liquid Assets | ₩104.36 Billion | 21.48% |
Asset Resilience Insights
- Good Liquidity Position: United Pharm maintains a healthy 21.48% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
United Pharm Industry Peers by Asset Resilience Ratio
Compare United Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for United Pharm (2011–2024)
The table below shows the annual Asset Resilience Ratio data for United Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.81% | ₩98.61 Billion | ₩473.93 Billion | -6.31pp |
| 2023-12-31 | 27.12% | ₩127.14 Billion | ₩468.86 Billion | -0.58pp |
| 2022-12-31 | 27.70% | ₩115.74 Billion | ₩417.89 Billion | +11.28pp |
| 2021-12-31 | 16.41% | ₩62.37 Billion | ₩380.03 Billion | +1.20pp |
| 2020-12-31 | 15.21% | ₩53.76 Billion | ₩353.43 Billion | +3.71pp |
| 2019-12-31 | 11.50% | ₩38.09 Billion | ₩331.24 Billion | -0.82pp |
| 2018-12-31 | 12.32% | ₩37.19 Billion | ₩301.95 Billion | +0.09pp |
| 2017-12-31 | 12.23% | ₩32.51 Billion | ₩265.80 Billion | +1.69pp |
| 2016-12-31 | 10.54% | ₩24.70 Billion | ₩234.22 Billion | +5.15pp |
| 2014-12-31 | 5.40% | ₩11.72 Billion | ₩217.10 Billion | +5.08pp |
| 2013-12-31 | 0.32% | ₩615.09 Million | ₩193.54 Billion | -4.67pp |
| 2012-12-31 | 4.99% | ₩9.36 Billion | ₩187.58 Billion | +4.76pp |
| 2011-12-31 | 0.23% | ₩384.56 Million | ₩170.09 Billion | -- |